Ipsen (IPN.PA) Saham Harga
Ipsen Harga
Selama 19 tahun terakhir pendapatan Ipsen tumbuh 7,9% per tahun, mencapai 3,68 miliar EUR. Laba per saham tumbuh 6,2% per tahun selama 19 tahun terakhir. Bagi Ipsen, margin bersih sebesar 12,1% turun dibanding 23,5% beberapa tahun lalu. Pada harga saat ini imbal hasil dividen sekitar 0,84%. Rasio pembayaran sekitar 26% dari laba. Dividen tumbuh 4,6% per tahun selama 19 tahun terakhir. Target harga konsensus 12 bulan untuk Ipsen adalah 132,60 EUR, sekitar di bawah harga saat ini 20,7%. Dari 19 analis, 8 merekomendasikan beli — konsensus keseluruhan Tahan.
Harga saham Ipsen
Akses data ini lewat Eulerpool API
100.000 permintaan/bulan gratis · tanpa kartu
Model bisnis dan analisis saham Ipsen
Pertanyaan yang sering diajukan tentang saham Ipsen
Ipsen SA represents values of innovation, integrity, and commitment to improving patient lives. With a strong corporate philosophy centered around patient-focused healthcare solutions, Ipsen SA strives to develop and deliver innovative treatments for complex diseases. The company's dedication to research and development, combined with a global network of partners, allows Ipsen SA to make a positive impact on the lives of patients worldwide.
Ipsen SA's business model revolves around the development, manufacturing, and commercialization of innovative pharmaceutical products for various therapeutic areas. As a global biopharmaceutical company, Ipsen focuses on specialty care and oncology, offering a diverse portfolio of drugs to address unmet medical needs. They aim to improve patients' lives through effective treatments, cutting-edge research, and collaborations with healthcare professionals. Ipsen's commitment to innovation and patient-centric solutions further strengthens their foothold in the pharmaceutical industry.
Ipsen SA is primarily active in the pharmaceutical industry.
The main competitors of Ipsen SA in the market include companies such as Novartis, Sanofi, and Merck KGaA.
Ipsen SA is a renowned pharmaceutical company with a rich history and background. Founded in 1929, Ipsen has grown to become a global leader in specialty care treatments for urology, oncology, and endocrinology. With a strong focus on innovation and research, Ipsen has developed a diverse range of products to address various medical needs. Over the years, the company has expanded its reach to more than 115 countries and collaborates with numerous partners to enhance patient care worldwide. Ipsen's commitment to improving patient outcomes through cutting-edge therapies and its global presence has solidified its position as a trusted name in the pharmaceutical industry.
Some significant milestones achieved by Ipsen SA include the acquisition of Clementia Pharmaceuticals in 2019, expanding its rare diseases portfolio, and the FDA approval of Cabometyx for advanced hepatocellular carcinoma in 2018. Ipsen SA has also made advancements in neurology, with the 2019 FDA approval of Dysport for pediatric lower limb spasticity. Furthermore, Ipsen SA has collaborated with partners to develop innovative treatments, such as the partnership with Exelixis for the development of Cabometyx. These milestones highlight Ipsen SA's commitment to research, development, and expanding treatment options in various therapeutic areas.
Ipsen SA is primarily present in various countries and regions globally. The company has a strong presence in Europe, with its headquarters based in France. Ipsen also has significant operations in the United States and several other countries across North and South America, including Canada and Brazil. Additionally, Ipsen has a growing presence in Asia, particularly in China and Japan, as well as key markets in the Middle East and Africa. With its widespread footprint, Ipsen SA aims to serve patients and healthcare professionals across multiple regions and provide its pharmaceutical solutions to a diverse and global community.
Analis saat ini menetapkan target harga rata-rata 135,82 EUR untuk saham Ipsen (median: 132,60 EUR), yaitu -18,8 % terhadap harga terbaru. Konsensus didasarkan pada 19 peringkat analis.
19 analis saat ini menilai saham Ipsen: 8 merekomendasikan beli, 9 tahan, dan 2 jual. Untuk 2026, analis memperkirakan Ipsen menghasilkan pendapatan 4,63 miliar EUR dan laba per saham 16,35 EUR.
Saham Ipsen (IPN.PA) tercatat di 8 bursa, termasuk: London (0MH6.L), Frankfurt (I7G.F), München (I7G.MU), Düsseldorf (I7G.DU), Wien (IPN.VI), Paris (IPN.PA).
Ipsen SA is a global pharmaceutical company based in Paris, France. The company specializes in the research, development, manufacturing, and marketing of medications used to treat cancer, neurological diseases, and rare diseases. Ipsen offers a wide range of products divided into three main business areas. 1. Oncology In the field of oncology, Ipsen offers therapies for the treatment of neuroendocrine tumors (NET), prostate cancer, and pancreatic cancer. The company also has a promising pipeline of medications for the treatment of various types of cancer. 2. Neuroscience Ipsen is a leading provider of therapies for the treatment of neurological diseases such as spasticity, cerebral palsy, and migraines. Products in this area include Dysport, an injectable botulinum toxin, as well as numerous other orally-administered medications. 3. Rare Diseases Ipsen has also specialized in the development and marketing of therapies for the treatment of rare diseases. Products in this area include Somatuline for the treatment of acromegaly and neuroendocrine tumors, as well as Increlex for the treatment of short stature. In addition, Ipsen has a strong presence in Europe, North America, and the Asia-Pacific region. The company has built a large network of subsidiaries, distribution partners, and licensees that allows it to market its products worldwide. Ipsen also relies on innovative partnerships and strategic acquisitions to strengthen its market presence. In 2020, the company acquired Clementia Pharmaceuticals, a company specializing in the development of therapies for the treatment of rare bone diseases such as fibrodysplasia ossificans progressiva (FOP). Overall, Ipsen's business model is based on a strong research and development department that focuses on identifying new therapies and improving existing treatment options. The company works closely with medical professionals, academic institutions, and other industry partners. Ipsen also strives for sustainable corporate development by focusing on environmentally-friendly practices and ethical business practices. The company is committed to carbon-neutral production and supports social projects worldwide. Overall, Ipsen has built a robust business model supported by its strong presence in the global market, its products in various therapy areas, and its innovative research and development department.
Pendapatan diperkirakan dari Ipsen adalah 4,63 miliar EUR. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba diperkirakan dari Ipsen adalah 1,34 miliar EUR. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) Ipsen saat ini adalah 10,23. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Ipsen.
Rasio harga-terhadap-penjualan (PSR) Ipsen saat ini adalah 2,97. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Ipsen.
Skor Kualitas AlleAktien untuk Ipsen adalah 6/10.
ISIN dari Ipsen adalah FR0010259150. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari Ipsen adalah A0ESMG. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari Ipsen adalah IPN.PA. Simbol ticker digunakan untuk memperdagangkan saham Ipsen di bursa saham.
Saham Ipsen
Kelompok Peer Ipsen
Ipsen Ticker
Ipsen FIGI
Semua metrik fundamental dan analisis mendalam Ipsen
Analisis saham kami untuk saham Ipsen mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Ipsen. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.